Key result
Combination treatment with Bosentan and Sildenafil lowered pulmonary vascular resistance, normalized cardiac output, and increased right ventricular mitochondrial capacity in rats with PAH.
Why the study?
Does combination treatment with Bosentan and Sildenafil improve right ventricular function and mitochondrial capacity in a rat model of pulmonary arterial hypertension?
Population
Male Wistar rats with monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH)
Comparison
Combination treatment with Bosentan and… vs Monotreatment with Bosentan or Sildenafil, and…
Design
Preclinical
Follow-up
10 days
Authors
Loading...
Hypothesis-generating for RV mitochondrial effects in PAH models; requires human trials before any clinical consideration.
Does combination treatment with Bosentan and Sildenafil improve right ventricular function and mitochondrial capacity in a rat model of pulmonary arterial hypertension?
Combination therapy with Bosentan and Sildenafil improves right ventricular adaptation in pulmonary arterial hypertension through both pulmonary vascular resistance reduction and direct mitochondrial effects.
Mouchaers et al. (2009) studied Pulmonary arterial hypertension. Bosentan and Sildenafil combination vs. Monotreatment (Bosentan or Sildenafil) and untreated control was evaluated on Right ventricular function and oxidative metabolism. Combination treatment with Bosentan and Sildenafil lowered pulmonary vascular resistance, normalized cardiac output, and increased right ventricular mitochondrial capacity in rats with PAH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: